Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Catridecacog
Introduction
Overview
Overview
Catridecacog (brand name Tretten) is a class of recombinant factor XIII A-subunit based medication, indicated in patients with a rare clotting disorder, congenital factor XIII A-subunit deficiency. The medication prevents bleeding in patients with this condition, and has been approved by the U.S. Food and Drug Administration (FDA) for this use in the US in 2014.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]